All In Biotech

Drug Trial Radar · NCT07212426

Efficacy, Safety, and Pharmacokinetics of LP-005 Injection in PNH Patients.

A Phase II, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of LP-005 Injection in Patients With Paroxysmal Nocturnal Hemoglobinuria.

Last checked: Nov 19, 2026Latest source record: Jan 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

30

Actual

Start

Nov 14, 2024

Primary completion

May 6, 2026

Study completion Mar 31, 2028

Sponsor

Lead sponsor
Longbio PharmaIndustry
Sponsor type
Industry
First posted
Oct 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, open-label, Phase II clinical study to evaluate the efficacy, safety, and pharmacokinetics of LP-005 injection in adult patients with paroxysmal nocturnal hemoglobinuria (PNH).

Conditions

  • PNH - Paroxysmal Nocturnal Hemoglobinuria

Interventions

  • LP-005 InjectionBiological

    IV infusion, Q4W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in serum lactate dehydrogenase (LDH) levels.Time frame: Baseline and at Week 12.
  2. Proportion of participants with ≥2 g/dL increase in hemoglobin level from Baseline in the absence of transfusion.Time frame: Baseline and at Week 24.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Nanjing Medical University

    Nanjing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.